Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibition.

Saved in:
Bibliographic Details
Title: Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibition.
Authors: Wilkinson S; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Ku AT; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Lis RT; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., King IM; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Low D; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Trostel SY; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Bright JR; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Terrigino NT; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Baj A; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Summerbell ER; Office of Intramural Research, National Institutes of Health, Bethesda, Maryland, USA., Heyward KE; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Kartal S; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Fenimore JM; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Li C; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Singler C; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Vo B; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA., Jansen CS; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA., Ye H; Department of Pathology and Department of Urology, UCLA, Los Angeles, California, USA., Whitlock NC; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Harmon SA; Molecular Imaging Branch., Carrabba NV; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Atway R; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Lake R; Laboratory of Cancer Biology and Genetics, and., Takeda DY; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Kissick HT; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA., Pinto PA; Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Choyke PL; Molecular Imaging Branch., Turkbey B; Molecular Imaging Branch., Dahut WL; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Karzai F; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Sowalsky AG; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Source: The Journal of clinical investigation [J Clin Invest] 2025 Sep 04; Vol. 135 (22). Date of Electronic Publication: 2025 Sep 04 (Print Publication: 2025).
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: eCollection Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI189900